See other companies on Welcome to the Jungle
Beacon Biosignals
AI brain monitoring
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Machine Learning
- MedTech
- Beacon Hill, Boston, MA
Jump to section
Company mission
To improve human health by enabling rapid, targeted interventions through advanced brain analytics.
Our take
The brain has long been considered one of the most mysterious fields of medicine - and psychiatric and neurological diseases therefore one of the least understood. Better access to real-time brain data, however, could change this. That’s exactly what Beacon Biosignals is hoping to deliver.
Beacon Biosignals has developed a scaleable electroencephalogram (EEG) analytics platform that leverages AI to more accurately and insightfully manage brain data. Its capabilities run from analysing existing data, to identifying and standardizing neorobiomarkers, to continuously aggregating and analyzing trial data.
The hope is that this will help clinical brain researchers carry out faster and more accurate work, ultimately accelerating the pace of treatment development in neurology. It’s a smart new AI application, and Beacon Biosignals is acquiring new companies to scale and receiving handsome funding - but for that reason the company isn’t alone in pursuing it. Bitbrain is also developing neurology AI, although with a tighter focus on product development. This may help differentiate Beacon Biosignals in what is still a relatively new market area.
Kirsty
Company Specialist at Welcome to the Jungle
Company values
- The highest quality science is performed by teams. It's also more fun
- Successful product development requires rapid, early feedback from real patients and clinicians
- Feats of technical wizardry are only useful in combination with honest, frequent, and open communication
- A diverse team builds more robust systems and practices more impactful science
Funding (last 2 of 3 rounds)
Nov 2021
$27m
SERIES A
Jun 2019
$3m
SEED
Total funding: $30.5m
This company has top investors
Leadership
Jarrett Revels
(CTO)Previously a Software Engineer at MissionFocus, who then moved into various engineering and research roles at MIT.
Jacob Donoghue
(CEO)Completed a Neuroscience PhD at MIT, and received his MD from Harvard Medical School. Subsequently carried out research for Cyberkinetics Neurotechnology Systems and Massachusetts General Hospital.
Brandon Westover
(Co-founder)Received his MD from Washington University School of Medicine, then took up a Neurology residency at Harvard Medical School. Alongside his work at Beacon Biosignals, is also an HST Faculty member at MIT and a Neurologist/Medical AI Researcher at Massachusetts General Hospital.
Syd Cash
(Co-founder)An Associate Professor at Harvard Medical School, who also leads the Center for Neurotechnology and Neurorecovery at MGH.
Articles
Jobs (5)
Marketing
Operations & Strategy
Design
Other Engineering